In the US the tax payer subsidizes almost all drug research. Between 2010 and 2019 the NIH spent $184 Billion on all but 2 drugs approved by the FDA.

It worked out to about $1.5 Billion for each R&D product with a novel target and about $600 mill for each R&D product with multiple targets.

https://pmc.ncbi.nlm.nih.gov/articles/PMC10148199/

Or

https://jamanetwork.com/journals/jama-health-forum/fullarticle/2804378

The cost to develop each drug is between about $1 and $2.5 Billion

I’m not sure how much is subsidized outside of NIH but I’d imagine other countries are doing the same.

Why should companies own the whole IP or perhaps why should they have any ownership if most of the funding is from the public?

Dual boot with Windows is terrible because of how fastboot messes with the drive partitions. If you want to dual boot you will have to turn off Windows fastboot.

Needing to use command line for some things that should be a right click, not supporting right click, ambiguities galore when looking at a package repository, odd defaults in packages that one really wouldn’t expect to have to check (e.g. Selecting RDP connection in a Remote app, but it defaults the security to something other than RDP?)

Sounds like you’re using a GNOME Desktop. You should give KDE Plasma a try instead. KDE Plasma basically gives you a Windows-esq experience without trying to install something like GNOME extensions.

For a regular user there’s not much point into going into the command-line anymore.

there’s problems like Libre Office devs …

Sure but there’s also alternatives. LibreOffice doesn’t try to emulate Microsoft Office and they never really have. They won’t even try to be compatible with MS Office but rather they do with OOXML which Microsoft created for other Office suites to be compatible with it but then just never supported it very well. Some alternatives do however. WPS Office is perhaps the most popular alternative for this that does try to be compatible with MS Office and emulate its feel and features but ONLYOFFICE is also a contender.